We analyzed high molecular weight polysaccharide (PS) from the Fisher immunotype 2 (IT-2) strain of Pseudomonas aeruginosa for molecular composition and structure, then determined its immunogenicity in healthy adults. The PS was composed of 2-acetamido-2,6-dideoxygalactose (N-acetyl fucosamine) and glucose in a molar ratio of 2:1. Structural analysis by carbon-13 and proton nuclear magnetic resonance confirmed that the high molecular weight PS was structurally identical to that of the O-specific side chain of the lipopolysaccharide. PS differed from this material in molecular size. Immunization of 19 adult volunteers with doses of 50-100 micrograms of PS resulted in significant rises (P less than 0.04-P less than 0.0001) in binding antibody levels and killing antibody titers 2 and 4 wk postimmunization. The only reaction to the vaccine was localized tenderness at the immunization site. Analysis of the immunoglobulin isotype response to the vaccine showed a rise in specific serum IgG and IgA antibodies. Heterologous responses to other P. aeruginosa PS antigens were not seen. The antibody levels attained by vaccination were comparable with those in acute-phase serum samples of patients who survived sepsis with IT-2 P. aeruginosa and were significantly higher (P less than 0.03) than specific antibody levels in bacteremic patients who died. These results confirm that PS is a high molecular weight, immunogenic form of the P. aeruginosa IT-2 serotype antigen, eliciting levels of type-specific antibody comparable with those seen among patients surviving an episode of P. aeruginosa sepsis.
G B Pier, S E Bennett
Title and authors | Publication | Year |
---|---|---|
Pseudomonas
JL Ramos, JB Goldberg, A Filloux |
2014 | |
Novel conjugate vaccine for the prevention ofPseudomonas aeruginosa infection in cystic fibrosis patients
KL Matson, JP Bratberg |
Drug Development Research | 2007 |
Pseudomonas aeruginosa: the potential to immunise against infection
E Sedlak-Weinstein, AW Cripps, JM Kyd, AR Foxwell |
Expert Opinion on Biological Therapy | 2005 |
Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen
GB Pier |
Carbohydrate Research | 2003 |
Ullmann's Encyclopedia of Industrial Chemistry
J Sandow, E Scheiffele, M Haring, G Neef, K Prezewowsky, U Stache |
Ullmann's Encyclopedia of Industrial Chemistry | 2000 |
Complex Serology and Immune Response of Mice to Variant High-Molecular-Weight O Polysaccharides Isolated fromPseudomonas aeruginosa Serogroup O2 Strains
K Hatano, GB Pier |
Infection and immunity | 1998 |
Pseudomonas aeruginosa antigens as potential vaccines
ES Stanislavsky, JS Lam |
FEMS Microbiology Reviews | 1997 |
Pseudomonas aeruginosa lipopolysaccharides and pathogenesis
JB Goldberg, GB Pier |
Trends in Microbiology | 1996 |
Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: Experimental studies in animals
HK Johansen |
APMIS | 1996 |
Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06
GB Pier, NL Koles, G Meluleni, K Hatano, M Pollack |
Infection and immunity | 1994 |
Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection
HK Johansen, F Espersen, SJ Cryz, HP Hougen, A Fomsgaard, J Rygaard, N Høiby |
Infection and immunity | 1994 |
Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa
K Hatano, S Boisot, D DesJardins, DC Wright, J Brisker, GB Pier |
Infection and immunity | 1994 |
Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody
JF Pittet, MA Matthay, G Pier, M Grady, JP Wiener-Kronish |
Journal of Clinical Investigation | 1993 |
Occurrence of a 29 kDa polysaccharide in the slime layer of both smooth and rough strains of Pseudomonas aeruginosa
M Christofidou, NK Karamanos, AC Mintzas, G Dimitracopoulos, ED Anastassiou |
International Journal of Biochemistry | 1993 |
Release of Interleukin-8, Interleukin-6, and Colony-stimulating Factors by Upper Airway Epithelial Cells: Implications for Cystic Fibrosis
M Bédard, CD McClure, NL Schiller, C Francoeur, A Cantin, M Denis |
American journal of respiratory cell and molecular biology | 1993 |
Pseudomonas aeruginosa as an Opportunistic Pathogen
M Campa, M Bendinelli, H Friedman |
1993 | |
Type-specific carbohydrate antigens of pathogenic bacteria. Part 2
AJ Griffiths, DB Davies |
Carbohydrate Polymers | 1991 |
Increased elastase secretion by peripheral blood monocytes in cystic fibrosis patients
MM Jones, DK Seilheimer, GB Pier, RD Rossen |
Clinical & Experimental Immunology | 1990 |
Polysaccharide Antigens of Pseudomonas Aeruginosa
YA Knirel |
Critical Reviews in Microbiology | 1990 |
Increased elastase secretion by peripheral blood monocytes in cystic fibrosis patients.
Jones MM, Seilheimer DK, Pier GB, Rossen RD |
Clinical & Experimental Immunology | 1990 |
In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide
GB Pier, D Thomas, G Small, A Siadak, H Zweerink |
Infection and immunity | 1989 |
Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide
GB Pier, M Pollack |
Infection and immunity | 1989 |
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans
SJ Cryz, E Fürer, AS Cross, A Wegmann, R Germanier, JC Sadoff |
Journal of Clinical Investigation | 1987 |
Prospects for the prevention and control of Gram-negative nosocomial infections
SJ Cryz |
Vaccine | 1987 |